检索结果-南通市图书馆

Dysregulation of PLOD2 Promotes Tumor Metastasis and Invasion in Hepatocellular Carcinoma

Journal of Clinical and Translational Hepatology 2023年第5期11卷 1094-1105页

作者： Keren li Yi Niu Kai li Chengrui Zhong Zhiyu Qiu Yichuan Yuan Yunxing Shi Zhu lin Zhenkun Huang Dinglan Zuo Yunfei Yuan binkui li State Key Laboratory of Oncology in South China Sun Yat-Sen University Cancer CenterGuangzhouGuangdongChina Department of liver Surgery Sun Yat-Sen University Cancer CenterGuangzhouGuangdongChina

Background and Aims:Metastasis is a major factor associated with high recurrence and mortality in hepatocellular carcinoma(HCC)patients while the underlying mechanism of metastasis remains *** our study,procollagen-lysine,2-oxoglutarate 5-dioxygenase 2(PLOD2)was shown to be involved in the process of metastasis in ***:The Cancer Genome Atlas(TCGA)database and HCC tissue microarrays were used to evaluate the expression of *** vitro migration,invasion,in vivo subcutaneous tumor model and in vivo lung metastasis assays were used to determine the role of PLOD2 in tumor growth and metastasis in *** sequencing and gene set enrichment analysis were performed to uncover the downstream factor of PLOD2 in HCC cells.A luciferase reporter assay was performed to evaluate the interaction between PLOD2 and interferon regulatory factor 5(IRF5).Results:The expression of PLOD2 in HCC tissues was higher than that in adjacent tissues,and increased PLOD2 expression was often found in advanced tumors and was correlated with poor prognosis in HCC *** vitro experiments,knockdown of PLOD2 reduced the migration and invasion of human HCC *** of PLOD2 suppressed human HCC growth and metastasis in a subcutaneous tumor model and a lung metastasis *** IAP repeat containing 3(BIRC3)was proven to be the downstream factor of PLOD2 in human HCC *** addition,PLOD2 was transcriptionally regulated by IRF5 in HCC ***:High expression of PLOD2 was regulated by IRF5,which was correlated with the poor survival of HCC ***2 enhanced HCC metastasis via BIRC3,suggesting that PLOD2 might be a valuable prognostic biomarker for HCC treatment.

关键词： PLOD2 Hepatocellular carcinoma Metastasis Invasion Proliferation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial

引用

Cancer Communications 2024年第11期44卷 1337-1349页

作者： Yichuan Yuan Hong Peng Wei He Yun Zheng Jiliang Qiu Bin Chen Ruhai Zou Chenwei Wang Wan Yee Lau binkui li Yunfei Yuan State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for CancerSun Yat-sen University Cancer CenterGuangzhouGuangdongP.R.China Department of liver Surgery Sun Yat-sen University Cancer CenterGuangzhouGuangdongP.R.China The Center of Hepatocellular-pancreatobiliary Surgery The First Affiliated HospitalSun Yat-sen universityGuangzhouGuangdongP.R.China Department of Ultrasound Sun Yat-sen University Cancer CenterGuangzhouGuangdongP.R.China Faculty of Medicine The Chinese University of Hong KongHong KongSARP.R.China

Background:The widely accepted view that portal hypertension(PHT)is a con-traindication to hepatectomy for patients with hepatocellular carcinoma(HCC)is being increasingly *** long-term survival outcomes and safety of partial hepatectomy versus interventional treatment using ablation with or without pre-ablation transarterial chemoembolization(TACE)in patients with HBV-related HCC within the Milan criteria and with clinically significant PHT were compared in this ***:This open-label randomized clinical trial was conducted on consecu-tive patients with clinically PHT and hepatitis B virus(HBV)-related HCC with tumors which were within the Milan *** patients were randomized 1:1 to receive either partial hepatectomy or interventional treatment between December 2012 and June *** primary endpoint was overall survival(OS);secondary endpoints included recurrence-free survival(RFS)and therapeutic ***:Each of the 2 groups had 80 *** 1-,3-and 5-year OS rates in the partial hepatectomy group and the interventional treatment group were 95.0%,86.2%,69.5%versus 93.8%,77.5%,64.9%,respectively(P=0.325).The corresponding RFS rates were 78.8%,55.0%,46.2%versus 71.3%,52.5%,45.0%,respectively(P=0.783).The partial hepatectomy group had a higher compli-cation rate compared to the interventional group(67.5%vs.20%,Plications(P0.05).Conclusions:This study shows that partial hepatectomy treatment did not meet prespecified significance for improved OS and RFS compared to interventional treatment for patients with HBV-related HCC within the Milan criteria and with clinically significant ***,partial hepatectomy is still a safe procedure and should be considered as a treatment option rather than a contraindication.

关键词： hepatocellular carcinoma portal hypertension partial hepatectomy interventional treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Overexpression of amplified in breast cancer 1 (AIB1) gene promotes lung adenocarcinoma aggressiveness in vitro and in vivo by upregulating C-X-C motif chemokine receptor 4

引用

Cancer Communications 2018年第1期38卷 572-585页

作者： liru He Haixia Deng Shiliang liu Jiewei Chen binkui li Chenyuan Wang Xin Wang Yiguo Jiang Ningfang Ma Mengzhong liu Dan Xie The State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer MedicineSun Yat-Sen University Cancer CenterNo.651Dongfeng Road EastGuangzhou 510060China Department of Radia-tion Oncology Sun Yat-Sen University Cancer CenterGuangzhouChina Department of Thoracic Oncology Sun Yat-Sen University Cancer CenterGuangzhouChina The State Key Laboratory of Respiratory Disease Guang-zhou Medical UniversityGuangzhouChina Key Laboratory of Protein Modification and Degradation School of Basic Medical SciencesAffiliated Cancer Hospital&Institute of Guangzhou Medical UniversityGuangzhouChina

Background:We previously found that overexpression of the gene known as amplified in breast cancer 1(AIB1)was associated with lymph node metastasis and poor prognosis in patients with lung ***,the role of AIB1 in that malignancy remains *** present study aimed to investigate the function of AIB1 in the process of lung adenocarcinoma cell ***:A series of in vivo and in vitro assays were performed to elucidate the function of AIB1,while real-time PCR and Western blotting were utilized to identify the potential downstream targets of AIB1 in the process of lung adenocarcinoma *** experiments and in vitro assays were performed to investigate whether the invasive-ness of AIB1-induced lung adenocarcinoma was mediated by C-X-C motif chemokine receptor 4(CXCR4).Results:The ectopic overexpression of AIB1 in lung adenocarcinoma cells substantially enhanced cell migration and invasive abilities in vitro and tumor metastasis in vivo,whereas the depletion of AIB1 expression substantially inhibited lung adenocarcinoma cell migration and ***4 was identified as a potential downstream target of AIB1 in lung *** knockdown of AIB1 greatly reduced CXCR4 gene expression at both the transcription and protein levels,whereas the knockdown of CXCR4 in cells with AIB1 ectopic overexpression diminished AIB1-induced migration and invasion in vitro and tumor metastasis in ***,we found a significant positive association between the expression of AIB1 and CXCR4 in lung adenocarcinoma patients(183 cases),and the co-overexpression of AIB1 and CXCR4 predicted the poorest ***:These findings suggest that AIB1 promotes the aggressiveness of lung adenocarcinoma in vitro and in vivo by upregulating CXCR4 and that it might be usable as a novel prognostic marker and/or therapeutic target for this disease.

关键词： Lung adenocarcinoma Amplified in breast cancer 1 C-X-C motif chemokine receptor 4 Metastasis Prognosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study

引用

Cancer Communications 2018年第1期38卷 280-290页

作者： Wei He Yun Zheng Ruhai Zou Jingxian Shen Junping Yang Jiliang Qiu Qiang Tao Wenwu liu Zhiwen Yang Yuanping Zhang binkui li Yunfei Yuan State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer MedicineSun Yat-Sen University Cancer Center651 Dongfeng Road EastGuangzhou 510060China Department of Hepatobiliary Oncology Sun Yat-Sen University Cancer CenterGuangzhou 510060China Department of Ultrasound Sun Yat-Sen University Cancer CenterGuangzhou 510060China Department of Medical Imaging Sun Yat-Sen University Cancer CenterGuangzhou 510060China

Background:Average postoperative follow-up intervals vary in patients undergoing hepatocellular carcinoma(HCC)resection because of limited evidence regarding the optimal *** aimed to compare the associations of long-versus short-interval follow-up with survival and recurrence in risk-stratified HCC ***:We performed a retrospective cohort study between 2007 and *** total,1227 patients treated by curative resection of Barcelona Clinic liver Cancer stage A or B HCC were stratified as having a low(n=865)or high(n=362)risk of early recurrence(within the first 2 years after resection)based on prognostic factors identified by the least absolute shrinkage and selection operation *** were further classified into long-interval(every 4-6 months)and short-interval(every 2-4 months)follow-up subgroups based on follow-up within 2 years after resection(low risk,long ***:n=390 vs.n=475;high-risk,long ***:n=149 vs.n=213).Results:The short-interval follow-up did not prolong overall survival in either the low-risk(hazard ratio[HR]=1.152;95%confidence interval[CI]0.720-1.843)or high-risk(HR=1.213;95%CI 0.702-2.094)*** recurrence occurred in 401 *** high-risk patients,the short-interval follow-up subgroup exhibited smaller intrahepatic recurrence than did the long-interval group(2.6 vs.3.5 cm,respectively,P=0.045).However,no significant difference in the rate of Barcelona Clinic liver Cancer stage 0/A recurrence was found between the long-and short-interval follow-up groups in either low-or high-risk patients(63.1%vs.68.2%,respectively,P=0.580;31.3%vs.41.5%,respec-tively,P=0.280).The rate of curative intent treatment for recurrence(34.5%vs.39.7%,respectively,P=0.430;14.6%vs.20.3%,respectively,P=0.388)was also similar between the follow-up groups for low-and high-risk ***:Shortening the postoperative follow-up interval from every 4-6 months to every 2-4 months within the first 2 years after resection d

关键词： Hepatocellular carcinoma Hepatectomy Prognosis Surveillance Recurrence

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

不可切除肝内胆管细胞癌的转化治疗

引用

中华肝脏外科手术学电子杂志 2023年第5期12卷 511-516页

作者：李斌奎中山大学肿瘤防治中心肝脏外科广州510060

肝内胆管细胞癌(ICC)是常见的肝脏原发恶性肿瘤之一,起源于肝内胆管分支衬覆上皮细胞,以腺癌最为多见。2020年统计约有906000例新发原发性肝癌,其中ICC占10%~15%,即9.1~13.6万例[1]。ICC的发病率在全球范围内呈上升趋势,欧美国家的发病... 详细信息

肝内胆管细胞癌(ICC)是常见的肝脏原发恶性肿瘤之一,起源于肝内胆管分支衬覆上皮细胞,以腺癌最为多见。2020年统计约有906000例新发原发性肝癌,其中ICC占10%~15%,即9.1~13.6万例[1]。ICC的发病率在全球范围内呈上升趋势,欧美国家的发病率较低,但在泰国和中国等地区发病较高[2]。ICC的危险因素包括肝硬化、乙型/丙型病毒性肝炎、饮酒、糖尿病、肥胖、吸烟、非酒精性脂肪性肝炎和肝吸虫感染,以及胆道疾病,如原发性硬化性胆管炎、肝内胆管结石、先天性胆管扩张症、Caroli病和炎症性肠病等[3]。

关键词：肝内胆管细胞癌胆管肿瘤转化治疗肝动脉灌注化疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

肝癌切除术后的长间隔与短间隔随访:一项回顾性队列研究

引用

癌症 2018年第12期37卷 533-544页

作者： Wei He Yun Zheng Ruhai Zou Jingxian Shen Junping Yang Jiliang Qiu Qiang Tao Wenwu liu Zhiwen Yang Yuanping Zhang binkui li Yunfei Yuan 中山大学肿瘤防治中心肿瘤医学合作创新中心华南肿瘤学国家重点实验室中山大学肿瘤防治中心肝胆肿瘤科中山大学肿瘤防治中心超声科中山大学肿瘤防治中心医学影像科

背景与目的由于缺乏证据证明肝细胞癌(hepatocellular carcinoma,HCC)切除术后的最佳随访间隔,术后患者接受随访的平均时间间隔不同。我们的目的是比较长间隔随访和短间隔随访与生存和复发的相关性在不同风险分层肝癌患者中的差异。方... 详细信息

背景与目的由于缺乏证据证明肝细胞癌(hepatocellular carcinoma,HCC)切除术后的最佳随访间隔,术后患者接受随访的平均时间间隔不同。我们的目的是比较长间隔随访和短间隔随访与生存和复发的相关性在不同风险分层肝癌患者中的差异。方法我们在2007年至2014年期间进行了一项回顾性队列研究。共有1227例巴塞罗那临床肝癌分期A期或B期的患者接受了根治性切除术。根据最小绝对收缩和选择操作算法为基础的预后因素分析,我们将患者分层为有低风险(n=865)或高风险(n=362)早期复发(切除术后2年内)的2组。根据切除术后2年内的随访情况,患者进一步分为长间隔(每4–6个月)随访和短期间隔(每2–4个月)随访的亚组(低风险,长期vs.短期:n=390 vs. n=475;高风险,长期vs.短期:n=149 vs. n=213)。结果不管在低风险[风险比(hazard ratio,HR)=1.152;95%置信区间(confidenceinterval,CI):0.720–1.843]还是高风险(HR=1.213;95%CI:0.702–2.094)患者中,短间隔随访没有延长患者的总生存期。401例患者出现早期复发。在高风险患者中,与长间隔随访组相比,短间隔组肝内复发肿瘤较小(2.6 cm vs. 3.5 cm,P=0.045)。但是,对于巴塞罗临床肝癌分期0/A期,长间隔与短间隔随访不管在低风险还是高风险患者中复发率(63.1%vs. 68.2%,P=0.580;31.3%vs. 41.5%,P=0.280)差异均无统计学意义。类似的,根治性切除术后,长间隔或短间隔随访分别在低风险和高风险患者中的复发率(34.5%vs. 39.7%,P=0.430;14.6%vs. 20.3%,P=0.388)差异也均无统计学意义。结论对于巴塞罗那临床肝癌分期A期或B期的患者,在接受了根治性切除术后的前2年内,将随访时间从4–6月缩短为2–4个月并不能增加根治性切除术的成功率或延长患者生存时间。

关键词：肝细胞癌肝切除术预后监测复发

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

结直肠癌肝转移诊疗新理念与新策略

引用

中华转移性肿瘤杂志 2018年第3期1卷 52-61页

作者：李斌奎陈功中山大学肿瘤防治中心肝胆胰外科广州510060 中山大学肿瘤防治中心结直肠外科广州510060

肝转移是结直肠癌最常见的转移模式.近年来,随着诊治理念的更新,外科技术的进步和可选用治疗手段的多样化,患者的预后也得到显著改善.本文就结直肠癌肝转移诊治中出现的一些新理念,包括寡转移与无疾病证据状态的定义与临床意义,可切除... 详细信息

肝转移是结直肠癌最常见的转移模式.近年来,随着诊治理念的更新,外科技术的进步和可选用治疗手段的多样化,患者的预后也得到显著改善.本文就结直肠癌肝转移诊治中出现的一些新理念,包括寡转移与无疾病证据状态的定义与临床意义,可切除标准的考量和发展,保留肝实质理念的临床应用,不同R1切缘类型对预后的影响,肝脏优先手术的理念,联合肝脏分隔和门静脉结扎二步肝切除术的探索,肝动脉灌注化疗及其他局部治疗的运用等进行阐述.同时介绍初始可切除及初始不可切除肝转移患者的总体治疗模式,包括新辅助化疗、辅助化疗、姑息化疗及靶向药物运用策略的一些新进展.

关键词：结直肠癌肝转移治疗策略

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

市域社会心理服务的实践研究

引用

西部现代职业教育研究 2023年第3期 26-31页

作者：刘敏岚李斌奎江西理工大学马克思主义学院江西赣州341000

我国的社会心理服务在顶层的助推下实现了跨跃式的发展。市域社会心理服务实践呈现出一系列特点,取得了宝贵的经验,但同时也存在一定的不足,如对社会心理服务实践的认识不足、服务的性质偏医疗、发展不平衡及相关制度不健全。本研究重... 详细信息

我国的社会心理服务在顶层的助推下实现了跨跃式的发展。市域社会心理服务实践呈现出一系列特点,取得了宝贵的经验,但同时也存在一定的不足,如对社会心理服务实践的认识不足、服务的性质偏医疗、发展不平衡及相关制度不健全。本研究重点从明确市域社会心理服务的责任主体、提升社会心理服务实践的理念、提高专业队伍的能力和规范社会心理服务的内容与领域方面探索市域社会心理服务的提升路径。

关键词：社会心理服务市域实践

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

48例复发性肝细胞癌再次切除术后的疗效及预后因素分析

引用

中国肿瘤临床 2010年第2期37卷 96-100页

作者：陈小菁周凯李斌奎黄亮李锦清张亚奇元云飞江西省人民医院干部外科华南肿瘤学国家重点实验室中山大学肿瘤防治中心肝胆科广州市510060 南昌大学第二附属医院血管外科

目的:分析复发性肝细胞癌行再次切除术后的疗效和影响预后的因素。方法:回顾性分析中山大学附属肿瘤医院和江西省人民医院1995年7月至2003年7月48例复发性肝细胞癌患者行再次肝切除术的临床病理资料,包括患者性别、年龄、原发肿瘤和复... 详细信息

目的:分析复发性肝细胞癌行再次切除术后的疗效和影响预后的因素。方法:回顾性分析中山大学附属肿瘤医院和江西省人民医院1995年7月至2003年7月48例复发性肝细胞癌患者行再次肝切除术的临床病理资料,包括患者性别、年龄、原发肿瘤和复发肿瘤的病理学特征、再次肝切除术前全身状况、复发的出现时间及生存期等,根据随访结果计算总生存率和无瘤生存率,并作单因素及多因素分析。结果:48例患者再次切除术后中位生存时间36.3个月,1、3、5年累积生存率分别为81.3%、45.8%、27.1%,1、3、5年无瘤生存率分别为70.8%、25.0%、16.7%。单因素分析结果显示:原发肿瘤TNM分期、原发肿瘤伴血管侵犯、复发间隔时间、复发肿瘤大小、复发肿瘤TNM分期、复发肿瘤伴血管侵犯影响再切除术后累积生存率;复发间隔时间、原发肿瘤TNM分期、复发肿瘤大小、复发肿瘤有无血管侵犯、复发肿瘤病理分级和AFP水平影响再切除术后无瘤生存率。多因素分析显示:复发间隔时间、复发肿瘤TNM分期是影响复发性肝癌再切除术后累积生存的独立危险因素;复发间隔时间、复发肿瘤大小是影响其无瘤生存的独立危险因素。结论:肝内复发间隔时间短(≤24个月)、复发肿瘤直径>5cm、复发肿瘤TNM分期越晚,提示再次切除术后预后不良。

关键词：肝细胞癌复发再切除预后

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

肝细胞癌合并门静脉高压症治疗的争议

引用

中华肝脏外科手术学电子杂志 2019年第2期8卷 87-90页

作者：何伟李斌奎元云飞中山大学附属肿瘤医院肝胆胰科广州510060

肝细胞癌(肝癌)的根治性治疗手段包括肝移植术、肝切除术和经皮肝肿瘤局部消融治疗,其中手术切除仍是最常见、最有效的治疗方法.中国80%~90%的肝癌患者合并肝硬化,而肝硬化是导致门静脉高压症的主要原因,临床中肝癌合并门静脉高压症并... 详细信息

肝细胞癌(肝癌)的根治性治疗手段包括肝移植术、肝切除术和经皮肝肿瘤局部消融治疗,其中手术切除仍是最常见、最有效的治疗方法.中国80%~90%的肝癌患者合并肝硬化,而肝硬化是导致门静脉高压症的主要原因,临床中肝癌合并门静脉高压症并不少见.目前国内外肝癌治疗指南对于肝癌合并门静脉高压症是否适宜行手术切除的问题,尚存在较大争议.本文通过分析比较国内外相关临床研究结果,探讨肝癌合并门静脉高压症是否适宜行手术切除.

关键词：癌,肝细胞高血压,门静脉外科手术

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：